Key Drivers
- High liquidity
- No revenue
- Significant burn
AIAI Summary
Alpha Tau's Japan approval and U.S. radioactive‑material license meaningfully de‑risk the previous binary clinical gamble by creating near‑term commercialization optionality and a tangible liquidity buffer, but the investment now hinges on converting Japan launch into measurable revenue/post‑market data and delivering on‑time positive U.S. pivotal/PMA outcomes to avoid dilutive financing and a sharp re‑rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •No revenue
- •Significant burn
DRTS is solvent with strong liquidity and low leverage (~$73M liquid assets vs $28.6M liabilities) but generated zero FY2025 revenue and heavy cash burn (FY net loss $42.6M, operating cash outflow $26.7M), leaving it balance-sheet-backed yet operationally unprofitable.
Price Behavior
Key Price Behavior Insights:
- •Below last month average
- •Strong support zone
- •Elevated volatility
Price sits slightly below its last month average (7.26) at $7.07, signaling a mild near-term downward bias with elevated short-term volatility (range ≈ $2.01 or ~28%) and key support around $6.41–$6.70 versus resistance at $7.76–$8.42.
Range of roughly $2.01 (~28% of last month average) indicates elevated short-term volatility
Sentiment & News
Key News Insights:
- •Japan approval
- •U.S. trial expansion
- •Market entry readiness
Alpha Tau Medical secured Japan's Shonin approval for Alpha DaRT in advanced/recurrent head and neck cancer and announced multiple parallel U.S. trials, new indications and investor outreach as it shifts toward commercialization.
The approval and concurrent trial progress materially de-risk commercial launch and should improve visibility and investor interest as revenue pathways in Japan and other indications accelerate
Similar Companies in Healthcare
Other companies in the same sector with AI ratings